Mibolerone and Processed for Either Mitogens Activate the Various Sequential Players in the Cell Cycle Fluorescence-Activated Cell Sorting Or Western Analysis

Total Page:16

File Type:pdf, Size:1020Kb

Mibolerone and Processed for Either Mitogens Activate the Various Sequential Players in the Cell Cycle Fluorescence-Activated Cell Sorting Or Western Analysis [CANCER RESEARCH 56, I5.W-1544. April I. 1 Androgens Regulate the Expression of Proliferating Cell Nuclear Antigen Posttranscriptionally in the Human Prostate Cancer Cell Line, LNCaP Jaime E. Perry and Donald J. Tindall1 Departments of Urology Research ¡J.E. P.. D. J. T.I and Biochemistry/Molecular Biology [D. J. TJ. Mayo Clinic Foundation. Rochester. Minnesota 55905 ABSTRACT for DNA polymerase 5-driven DNA synthesis (7, 8). This ubiquitous protein is cell cycle regulated. PCNA synthesis reaches a maximum Proliferating cell nuclear antigen (PCNA) expression is required for during the S phase of the cell cycle (9) and is required for DNA DNA replication. Because androgens are critical for prostate cell prolif synthesis and cell division ( 10). PCNA. as an index of tumor prolif- eration, we investigated the effects of androgen on PCNA expression in the erative activity, is used to gain insight into the process of neoplastic prostatic cancer cell line LNCaP. Flow cytometric analysis was used to measure cellular DNA content with dual labeling of PCNA. Semiconfluent progression and clinical patient management (II). LNCaP cells were grown in serum-free medium containing varying con Thus far, little is understood about the mechanisms by which centrations of the synthetic androgen mibolerone and processed for either mitogens activate the various sequential players in the cell cycle fluorescence-activated cell sorting or Western analysis. Supplementation events necessary for cell growth. The regulation of PCNA expression of serum-free medium with androgens resulted in dose-dependent changes appears to be cell type specific; epidermal growth factor and platelet- in PCNA immunorcactivity, with maximum stimulation (2-fold) being derived growth factor in BALB/c3T3 cells induce PCNA mRNA (12). achieved at 48 h with IO "Mmibolerone. Non-androgenic steroids did not whereas in thyroid epithelial cells, PCNA protein expression is in change PCNA immunoreactivity compared with untreated controls, and duced by thyroid-stimulating hormone via cAMP (13). the antiandrogen, casodex, inhibited the mibolcrone-stimulated increase In this paper, we present evidence for the androgenic regulation of in PCNA immunoreactivity, suggesting that the androgenic induction of the expression of PCNA protein in LNCaP cells. Our data suggest that PCNA is mediated through the androgen receptor. The presence of a non-consensus androgen response element in the promoter region of the it is unlikely that this regulation involves transcriptional events, since PCNA gene led us to investigate whether androgen responsiveness of the no change was observed in steady-state mRNA for PCNA in LNCaP PCNA gene in LNCaP cells might be mediated at the transcriptional level. cells with androgen treatment. We show that androgen treatment No change in steady-state mRNA for PCNA with androgen administration increases the expression of PCNA protein by at least two mechanisms: was observed. However, an investigation of the androgenic regulation of (a) an increase in its half-life as assessed by immunoprecipitation of PCNA protein stability indicated that androgen treatment increased the radioactively-labeled PCNA with androgen treatment; and (/;) an half-life of J5S-labeled PCNA protein. In addition, polysome run-off trans increase in the translational efficiency of PCNA as assayed by poly- lation assays demonstrated an increase in PCNA protein after a 6-h stimulation of LNCaP cells with 10~*M mibolerone. These data suggest some run-off translation. The regulation of PCNA protein expression by androgens in LNCaP cells likely occurs through the interaction of that androgen induction of prostate cell proliferation may be mediated, at androgens with the androgen receptor through posttranscriptional least in part, through PCNA at the posttranscriptional level. mechanisms. INTRODUCTION MATERIALS AND METHODS Prostate cancer ranks among the leading causes of death in men. Cells and Culture Conditions. LNCaP cells (ATCC, Rockville, MD) were Since both secretory functions and growth of the adult prostate are maintained in RPMI 1640 with glulamine and sodium bicarbonate. The me androgen regulated, the mechanism by which androgens support the dium was supplemented with the antibiotics penicillin and streptomycin, which growth of prostatic tissue in benign and malignant pathologies is an were added to a final concentration of 50 /j.g/ml and PCS (Biofluids. Rockville. important area of focus. Changes in the growth process between MD) to 5%. Cells were used between passages 25 and 50 after attaining about normal and malignant prostatic cells may provide important clues as 70% confluence. Cells were incubated in serum-free medium for 3 days prior to the best possible treatments for metastatic disease or even prevent- to treatment. Treatments were added with a change of serum-free medium. ative strategies. Treatments included mibolerone (DuPont/New England Nuclear. Boston. The androgen-sensitive cell line LNCaP. derived from a lymph MA), casodex (ICI 176.334: Zeneca Pharmaceuticals, Wilmington, DE). R5020 (New England Nuclear, Boston, MA) . diethylstilbestrol, dihydrotest- node carcinoma of the prostate ( 1), retains many of the characteristics osterone. 17-ß-estradiol, and dexamethasone (all from Steraloids. Wilton. of prostatic epithelial cells. LNCaP cells respond to androgen stimu NH). Control cells were treated with the volume of ethanol used to deliver the lation by transcriptionally activating the genes for, and subsequently secreting, prostate-specific glandular kallikreins (PSA2 and hK2: steroids (final concentration, 0.01%). Flow Cytometric Analysis. Flow cytometry was performed on LNCaP Refs. 2-4), and by increasing cell proliferation (5). This cell line cells as follows: cells were collected, washed, and dispersed in PBS. Disper provides a useful transition between normal prostatic epithelial cells sion of the cells into a single-cell suspension was accomplished by drawing the and other established prostate cancer cell lines that no longer express cells in PBS 10 times through a 26-gauge. blunt-ended needle. An aliquot of the androgen receptor and are. therefore, androgen insensitive. the cells was set aside for cell counts using a Coulter counter (Coulter Two DNA polymerases, a and 8, are essential for DNA synthesis Electronics, Hialeah. FL). The rest of the cells were fixed in \c/c paratormal- (6) and cell proliferation. PCNA serves as a requisite auxiliary protein dehyde in PBS with 30 /j.g/ml lysolecithin (ICN Biochemicals. Cleveland. OH) added to permeabilize the cells. The cells were washed in buffer A (3% BSA in PBS with 0.05% Tween 20), split into two sets, and incubated overnight Received 6/26/95; accepted 1/31/96. with either anti-PCNA (PCIO clone; 1:10; DAKO, Carpenteria, CA) or anti- The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked tulvi'rlisemenl in accordance with PSA (1:100; Hybritech, San Diego. CA) diluted in buffer A. After washing in 18 U.S.C. Section 1734 solely lo indicate this faci. buffer A, the cells were incubated for l h with a FITC-conjugated second 1To whom requests for reprints should be addressed, at Department of Urology antibody (GAM-FITC; 1:100; Organon Technika/Cappel. West Chester. PA) Research. Mayo Clinic Foundation. Rochester. MN 55905. Phone: (507) 284-8553; Fax: (507) 284-2384; E-mail: [email protected]. diluted in buffer A. washed, and treated with RNase (1 mg/ml: Sigma Chem 2 The abbreviations used are: PSA. prostate-specific antigen; PCNA, proliferating cell ical Co., St. Louis, MO) for 15 min at 37°C.Cells were suspended in buffer A nuclear antigen; GAPDH. glyceraldehyde-3-phosphate dehydrogenase. with 0.1 mg/ml final concentration of propidium iodide and analyzed on a 1539 Downloaded from cancerres.aacrjournals.org on October 2, 2021. © 1996 American Association for Cancer Research. ANDROGENS REGULATE PCNA IN LNCaP CELLS FACStar Plus flow cytometer (Beclon Dickinson. Sunnyvale, CA) at a wave Polysome Run-Off Translation Assay. LNCaP cells at 60-70% conflu length of 488 nm with a 620-nm pass filter. ence were placed in serum-free medium for 48 h. The medium was changed; Northern Analysis. Northern analysis was performed on RNA isolated by then 24 h later, mibolerone treatments were added for 12 h. Polysome isolation the lithium chloride/urea method (14). LNCaP cells were disrupted in 3 M was performed according to the method of Taylor and Schimke (17) with lithium chloride and 6 M urea. The DNA was sheared with an Ultra-Turrax minor modifications. Cells were collected and homogenized in cold buffer B homogenizer (24.000 rpm; Janke and Kunkel. Staufen, Germany). The solution (50 mM Tris-Cl, 25 mM NaCI. and 5 mM MgCU, pH 7.7; I ml/TI75 flask at was left overnight at 4°C, and RNA was separated by centrifugaron at 70% confluence) containing 0.25 M sucrose and 500 /xg/ml sodium heparin 107,000 X g. The pellet containing the RNA was dissolved in 0.1% SDS and (Sigma; 170 USP units/mg). The homogenate was centrifuged at 9,500 rpm (14,600 X £max)for 10 min at 4°C.One-tenth volume of 10% Triton X-100/ 0.2 mM EDTA and extracted with phenol:chloroform (1:1) and chloroform. The RNA was precipitated with 0.16 M sodium acetate in ethanol. Purified, 10% SDS was added to the supernatant and mixed in a homogenizer. Five ml total RNA (20 jig/lane) was separated in a 1% denaturing agarose gel and of supernatants were overlain on a discontinuous sucrose gradient of 2 ml 2.5 transferred to Hybond N blotting membrane (Amersham. Arlington Heights. M sucrose. 4 ml 1.0 M sucrose, and 0.6 ml 0.5 M sucrose, where each sucrose IL). Blots were cross-linked using an automatic UV Stratalinker (Stratagene. solution was made with buffer B and 500 /ng/rn' sodium heparin. Tubes were La Jolla. CA), prehybridized for I h at 42°Cin prehybridization solution (45% centrifuged at 41.(XX)rpm (2(X),(XX)X Aav)for 90 min at 4°C.Polysomes were deionized formamide, 5X SSC.
Recommended publications
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • 2010 Prohibited List
    The World Anti-Doping Code THE 2010 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2010 The Prohibited List 2010 19 September 2009 THE 2010 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2010 All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone
    [Show full text]
  • CHEQUE® DROPS CII Pharmacia & Upjohn Estrous Preventive Mibolerone Drops NADA No.: 102-709 Active Ingredient(S): Each Ml Co
    CHEQUE® DROPS CII Pharmacia & Upjohn Estrous Preventive Mibolerone drops NADA No.: 102-709 Active Ingredient(s): Each mL contains 100 mcg mibolerone and propylene glycol, qs. Indications: CHEQUE® (mibolerone) Drops are administered orally for estrous (heat) prevention in adult female dogs not intended primarily for breeding purposes. CHEQUE® Drops dosage should be discontinued after 24 months of use. CHEQUE® Drops are effective in preventing estrus only when drug administration is initiated 30 days prior to the start of the proestrus. It should not be used in an attempt to abbreviate an estrous period. It should not be used in bitches prior to the first estrous period. Pharmacology: CHEQUE® (mibolerone) Drops are 17-b-hydroxy-7a, 17-dimethyl-estr-4-en-3-one, generic name mibolerone, a non-progestational steroid. In its pure form, mibolerone is a white crystalline solid. The compound is stable under ordinary conditions and temperatures. Actions: More than 90 percent of normal, mature cycling bitches did not exhibit estrus when administered CHEQUE® (mibolerone) Drops in adequate doses. Mibolerone has been shown to be an anabolic and androgenic steroid in rats. When compared to methyltestosterone, it is 41 times more potent as an anabolic agent and 16 times more potent as an androgen. Mibolerone has no estrogenic activity in mice when used at levels up to 1.0 mg per animal per day. It is antiestrogenic in mice in intravaginal tests at 0.9 mcg and in subcutaneous tests at 10 mcg or less when tested against estradiol. In the bitch, mibolerone has androgenic, anabolic and antigonadotrophic activity.
    [Show full text]
  • Multi-Discipline Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212099Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA 212099 Multi-disciplinary Review and Evaluation Darolutamide/NUBEQA NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) 212099 Priority or Standard Priority Submit Date(s) February 26, 2019 Received Date(s) February 26. 2019 PDUFA Goal Date August 26, 2019 Division/Office Division of Oncology Products 1/Office of Hematology & Oncology Products Review Completion Date Established/Proper Name Darolutamide (Proposed) Trade Name Nubeqa Pharmacologic Class Androgen receptor inhibitor Code name 427492003 | Hormone refractory prostate cancer (disorder) Applicant Bayer Doseage form 300 mg tablets Applicant proposed Dosing NUBEQA 600 mg, (two 300 mg tablets) administered orally Regimen twice daily. Swallow tablets whole. Take NUBEQA with food. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Applicant Proposed NUBEQA is an androgen receptor inhibitor indicated for the Indication(s)/Population(s) treatment of patients with non-metastatic castration-resistant prostate cancer. Applicant Proposed Non-metastatic castration resistant prostate cancer (nmCRPC) SNOMED CT Indication Disease Term for each Proposed Indication Recommendation on Regular approval Regulatory Action Recommended
    [Show full text]
  • Mibolerone Metabolism in the Upa -SCID Chimeric Mice
    Lootens, L1), De Spaey, A1), Deventer, K1), Meuleman, P2), Leroux-Roels, G2), Van Eenoo, P1) Mibolerone Metabolism in the uPA+/+-SCID chimeric mice 1) DoCoLab, Department of Clinical Biology, Microbiology and Immunology, Ghent University, Zwijnaarde, Belgium 2) CEVAC, Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Ghent University and Hospital, Ghent, Belgium Abstract In the past, the chimeric mouse model has proven to be an excellent model to perform in vivo metabolic studies of anabolic steroids. The chimeric model consists of a transgenic uPA+/+- SCID mouse transplanted with functional primary human hepatocytes. A useful application of the chimeric mouse model is to reinvestigate the metabolism of known steroids. Mibolerone, mentioned on the WADA-prohibited list, was selected to perform an in vivo excretion study with the chimeric mice. For ethical reasons, this in vivo humanized animal model is more accessible than human volunteers to perform metabolic studies of anabolic steroids, since steroid use is often associated with serious side effects like liver toxicity. Mibolerone was administered to 3 chimeric mice having different degrees of chimerism and to 1 non-chimeric mouse (without human hepatocytes) as a control. Excreted urine was collected after 24 hours via special designed metabolic cages for small rodents. The results of pre- and post-administration mouse urine, after analysis with a GC-MS scan method and a LC-MS/MS open screenings method, were evaluated and discussed. Introduction For the purpose of anti-doping screening, detection of steroid metabolites in urine is necessary. The market of steroids is evolving continuously due to ethical concerns and the illegal production of testosterone-derivatives (for non-therapeutic use) in order to escape from the control mechanisms.
    [Show full text]
  • Female Infertility
    FEMALE INFERTILITY BASICS OVERVIEW Abnormal cycling, breeding failure, conception failure, or pregnancy loss The female dog is a “bitch;” the female cat is a “queen” SIGNALMENT/DESCRIPTION of ANIMAL Species Dogs and cats Breed Predilections Dog breeds susceptible to low levels of thyroid hormone (known as “hypothyroidism”) may have a higher number of cases of female infertility than other breeds; breeds susceptible to hypothyroidism include the golden retriever, Doberman pinscher, dachshund, Irish setter, miniature schnauzer, Great Dane, poodle, and boxer Mean Age and Range Animals of all ages; may be more common in old animals Dogs greater than 6 years of age—more likely to have underlying cystic endometrial hyperplasia, a condition in which the lining of the uterus thickens abnormally and contains fluid-filled sacs or cysts; may be susceptible to uterine infection and failure of conception or implantation Predominant Sex Female SIGNS/OBSERVED CHANGES in the ANIMAL Failure to cycle Too frequent cycling Failure to breed with a male Normal act of breeding, with no subsequent pregnancy or delivery or birth (known as “parturition”) Infertility caused by hormonal disease—signs of skin abnormality (such as hair loss [known as “alopecia”]); generalized (systemic) signs of disease (such as increased thirst [known as “polydipsia”] and increased urination [known as “polyuria”]) Known pregnancy (through physical examination, ultrasound examination) with no subsequent delivery or birth (parturition) CAUSES Previous surgical removal
    [Show full text]
  • The Effect of F877L and T878A Mutations on Androgen Receptor
    Published OnlineFirst May 16, 2016; DOI: 10.1158/1535-7163.MCT-15-0892 Cancer Biology and Signal Transduction Molecular Cancer Therapeutics The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide Stefan Prekovic1, Martin E.van Royen2, Arnout R.D.Voet3,4, Bart Geverts2, Rene Houtman5, Diana Melchers5, Kam Y.J. Zhang3, Thomas Van den Broeck1,6, Elien Smeets1, Lien Spans7, Adriaan B. Houtsmuller2,8, Steven Joniau6, Frank Claessens1, and Christine Helsen1 Abstract Treatment-induced mutations in the ligand-binding domain that lead to a decrease in steric clashes for enzalutamide. of the androgen receptor (AR) are known to change antagonists Ligand-binding assays confirmed that the F877L mutation into agonists. Recently, the F877L mutation has been described leads to an increase in relative binding affinity for enzaluta- to convert enzalutamide into an agonist. This mutation was mide, but only the combination with the T878A mutation seen to co-occur in the endogenous AR allele of LNCaP cells, resulted in a strong agonistic activity. This correlated with next to the T878A mutation. Here, we studied the effects of changes in coregulator recruitment and chromatin interactions. enzalutamide on the F877L and T878A mutants, as well as Our data show that enzalutamide is only a very weak partial the double-mutant AR (F877L/T878A). Molecular modeling agonist of the AR F877L, and a strong partial agonist of the revealed favorable structural changes in the double-mutant AR double-mutant AR. Mol Cancer Ther; 15(7); 1702–12. Ó2016 AACR. Introduction chemotherapy by a median of 4.8 months in comparison with the placebo group (5).
    [Show full text]
  • Characterisation of Chemical and Pharmacological Properties of New Steroids Related to Doping of Athletes
    In: W Schänzer, H Geyer, A Gotzmann, U Mareck (eds.) Recent Advances In Doping Analysis (14). Sport und Buch Strauß - Köln 2006 C. Ayotte, D. Goudreault, D. Cyr and J. Gauthier1, P. Ayotte and C. Larochelle2, and D. Poirier3 Characterisation of chemical and pharmacological properties of new steroids related to doping of athletes 1INRS-Institut Armand-Frappier, Pointe Claire, Canada 2Institut de Santé publique de Québec, U. Laval, Québec, Canada 3Centre de recherche en chimie médicinale, U. Laval, Québec, Canada In the USA, a female cyclist, T. Thomas, was banned for the use of norbolethone, a steroid which has been studied by the pharmaceutical industry in the 60s but not commercialised1. Later in 2004, following the characterisation of THG2 from a oily residue given to the American testing authorities, and in collaboration with the international athletic federation, several elite athletes’ samples were tested and found to contain that “designer” steroid. The properties of tetrahydrogestrinone were subsequently studied; it appears that THG is a potent androgen and progestin3. Public comments made by individuals involved in the “Balco” scandal were adding to the information coming from other sources, mainly informants, to the effect that other “designer”, potent and undetecTable steroids have been prepared and would be available to certain athletes. This has become a certainty in December 2003, following a seizure at the Canadian border of hGH, and two steroid-products one of which found to be THG. The identification of the second one, DMT (17α-methyl-5α-androst-2-en-17β-ol major isomer along with the 3-en isomer), is the subject of the first part of this work; picture of the bottle seized is shown at Figure 1.
    [Show full text]
  • Nandrolone Induces a Stem Cell-Like Phenotype in Human
    www.nature.com/scientificreports OPEN Nandrolone induces a stem cell-like phenotype in human hepatocarcinoma-derived cell line inhibiting mitochondrial respiratory activity Francesca Agriesti 1, Tiziana Tataranni1, Consiglia Pacelli2, Rosella Scrima2, Ilaria Laurenzana1, Vitalba Ruggieri1, Olga Cela2, Carmela Mazzoccoli1, Monica Salerno3, Francesco Sessa2, Gabriele Sani4,5, Cristoforo Pomara3, Nazzareno Capitanio2 & Claudia Piccoli 1,2* Nandrolone is a testosterone analogue with anabolic properties commonly abused worldwide, recently utilized also as therapeutic agent in chronic diseases, cancer included. Here we investigated the impact of nandrolone on the metabolic phenotype in HepG2 cell line. The results attained show that pharmacological dosage of nandrolone, slowing cell growth, repressed mitochondrial respiration, inhibited the respiratory chain complexes I and III and enhanced mitochondrial reactive oxygen species (ROS) production. Intriguingly, nandrolone caused a signifcant increase of stemness-markers in both 2D and 3D cultures, which resulted to be CxIII-ROS dependent. Notably, nandrolone negatively afected diferentiation both in healthy hematopoietic and mesenchymal stem cells. Finally, nandrolone administration in mice confrmed the up-regulation of stemness-markers in liver, spleen and kidney. Our observations show, for the frst time, that chronic administration of nandrolone, favoring maintenance of stem cells in diferent tissues would represent a precondition that, in addition to multiple hits, might enhance risk of carcinogenesis raising warnings about its abuse and therapeutic utilization. Nandrolone (ND), a synthetic testosterone analogue, is one of the most commonly abused anabolic androgenic steroids (AAS) worldwide. For its improved anabolic properties ND is widely clinically applied in treatment of chronic diseases associated with catabolic state such as burns, cornea healing and osteoporosis1.
    [Show full text]
  • Public Law 108–358 108Th Congress An
    PUBLIC LAW 108–358—OCT. 22, 2004 118 STAT. 1661 Public Law 108–358 108th Congress An Act To amend the Controlled Substances Act to clarify the definition of anabolic steroids and to provide for research and education activities relating to steroids and Oct. 22, 2004 steroid precursors. [S. 2195] Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, Anabolic Steroid Control Act of SECTION 1. SHORT TITLE. 2004. This Act may be cited as the ‘‘Anabolic Steroid Control Act 21 USC 801 note. of 2004’’. SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT. (a) DEFINITIONS.—Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended— (1) in paragraph (41)— (A) by realigning the margin so as to align with para- graph (40); and (B) by striking subparagraph (A) and inserting the following: ‘‘(A) The term ‘anabolic steroid’ means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes— ‘‘(i) androstanediol— ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and ‘‘(II) 3α,17β-dihydroxy-5α-androstane; ‘‘(ii) androstanedione (5α-androstan-3,17-dione); ‘‘(iii) androstenediol— ‘‘(I) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1- ene); ‘‘(II) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1- ene); ‘‘(III) 4-androstenediol (3β,17β-dihydroxy-androst-4- ene); and ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy-androst-5- ene); ‘‘(iv) androstenedione— ‘‘(I) 1-androstenedione ([5α]-androst-1-en-3,17-dione); ‘‘(II) 4-androstenedione (androst-4-en-3,17-dione); and ‘‘(III) 5-androstenedione (androst-5-en-3,17-dione); ‘‘(v) bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en- 3-one); ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene-3-one); ‘‘(vii) calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4- en-3-one); VerDate 11-MAY-2000 08:28 Nov 10, 2005 Jkt 029194 PO 00000 Frm 00525 Fmt 6580 Sfmt 6581 C:\STATUTES\2004\29194PT2.001 APPS10 PsN: 29194PT2 118 STAT.
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]